

Figure S1 PARVA downregulation do not affect PCa cells proliferation. (A,B) Cell viability as assessed by MTS assay at different time points, ranging from 0 to 72 h in C4-2 or LNCaP cells. (C) Colony formation assays performed on PARVA-knockdown and control C4-2 or LNCaP cells in 6-well cell culture plates.




Figure S2 PARVA overexpression influence EMT, Akt/PKB, and GSK3 β pathways. (A) The expression of E-cadherin, N-cadherin, β -Catenin, Snail, Slug and PARVA determined by western-blot of PARVA-overexpressing and control C4-2 cells. GAPDH was used as the loading control. (B) The expression of ILK, AKT-Pan, AKT-Ser473, AKT-Thr308, pGSK3 β -Ser9 and PARVA determined by western-blot of PARVA-overexpressing and control C4-2 cells. GAPDH was used as the loading control.

Table S1 shRNA and overexpression sequences used in this study

Target	Forward Sequence (5'-3')	Reverse Sequence (5'-3')
shScramble	TTCTCCGAACGTGTCACGTAT	TTCTCCGAACGTGTCACGTAT
shPARVA#1	CAGGGACCCTTGAAC TTAAA	CAGGGACCCTTGAAC TTAAA
shPARVA#2	CTGAGACCTTGGGCTAAATAA	CTGAGACCTTGGGCTAAATAA
shILK	ACGCTGCTATGGACGACATTT	AAATGTCGTCCATAGCAGCGT
PARVA-CDS	ATGGCCACCTCCCCGCAG	TCACTCCACGTTACGGTACTTG

Table S2 Primers used in this study

Definition	Forward Sequence (5'-3')	Reverse Sequence (5'-3')
PARVA	AAGTCTCCCACTCCCAAGTC	TCATTCTCCTCCAGCATCGT
GAPDH	CATTTCTGGTATGACAACGA	CTTCCTCTTGCTCTTGCT
α -Tublin	CCAGATGCCAAGTGACAAGAC	GTGCGAACTTCATCAATGACTG

Table S3 Antibodies used in this study

Antibodies	Source	Identifier
PARVA	Proteintech	Cat #11202-1-AP
ILK	Abcam	Cat #ab76468
β -actin	Santa Cruz Biotechnology	Cat #SC47778
GAPDH	Cell Signaling Technology	Cat #97166
Epithelial-Mesenchymal Transition (EMT) Antibody Sampler Kit	Cell Signaling Technology	Cat #9782T
Phospho-Akt Pathway Antibody Sampler Kit	Cell Signaling Technology	Cat #9916
Phospho-Erk1/2 Pathway Sampler Kit	Cell Signaling Technology	Cat #9911T